Gerresheimer, the German pharmaceutical-packaging company, agreed on Wednesday to sell two of its businesses to the private equity firm Apax for about €1.5 billion including debt. The company framed the deal in the language of strategy, saying it regains flexibility and can focus on higher-value drug delivery. Apax framed it as an opportunity, saying the businesses will finally have capital to invest and expand in the US.
Both framings are true, and both are polite. The more useful way to read the transaction is through the balance sheet that made it necessary, because this is a company selling some of its most dependable assets not primarily because it wants to, but because it needs the cash, and a sale made from that position tends to hand the long-term value to the buyer. The deal is a clean example of what happens when a distressed seller meets a patient one.
What is actually being sold
The two businesses are Centor, a US maker of prescription-drug packaging like pill vials, and the global Primary Packaging Plastics division, which makes plastic bottles and containers for medicines. Together they generated roughly €570 million in revenue last year and employ about 2,400 people across sixteen sites in nine countries. Apax's own description is the tell: it called them market leaders in prescription vials and primary pharmaceutical packaging, built on a decades-long reputation for quality and reliability.
Read that description again, because it is the key to the whole deal. These are not turnaround projects or speculative growth bets. They are stable, established, cash-generative businesses making essential, unglamorous products that pharmaceutical companies need in predictable volumes year after year. Prescription vials do not go out of fashion. This is the kind of boring, dependable, defensive cash flow that private equity prizes precisely because it is reliable, and it is exactly the kind of asset a company sells when it needs money more than it needs steadiness.
Why Gerresheimer is selling steadiness
The reason the company needs the money is not a secret, though its own framing softens it. Gerresheimer has spent the past two years under real financial and governance strain. Its shares fell sharply from their 2023 peak, it carried heavy debt after a large 2024 acquisition of the Italian packaging maker Bormioli Pharma, and it became the subject of an internal accounting investigation and regulatory scrutiny in Germany that delayed its financial results. The company has said the internal investigation concluded, and it continues to assess the matter; no wrongdoing has been formally adjudicated, and the point here is not the accounting question itself but its financial consequence, a company with stretched leverage and a need to restore confidence.
Against that backdrop, the CFO's own words are the honest core of the deal: the transaction is described as an important milestone in optimizing the capital and financing structure, decreasing leverage significantly. Translated, the company is selling assets to pay down debt. That is a legitimate and often sensible thing to do, but it is a different motive than the strategic-focus language suggests, and the difference matters for who gets the better end of the deal. A company selling to sharpen its strategy can wait for the right price. A company selling to reduce leverage under pressure has a weaker hand, because the need to sell is itself known to every potential buyer.
The trade underneath the trade
Look at what Gerresheimer keeps versus what it sells, and a second, riskier decision comes into view. It is parting with the stable, defensive plastic-packaging businesses in order to concentrate on higher-value, higher-growth products: injectable-drug delivery systems, syringes, auto-injectors, and the specialized packaging used for newer therapies, including the booming weight-loss drugs.
That is a coherent strategy, and it is also a trade of certainty for growth. The businesses being sold are reliable and defensive; the businesses being kept are more exciting and potentially more profitable, but also more competitive, more dependent on specific drug franchises, and more exposed to technological change. Some analysts have questioned, for instance, whether the specialized syringe formats tied to particular blockbuster drugs face duration risk if those therapies shift toward oral pills or simpler, lower-margin delivery formats over time. That is a contested view rather than an established fact, but it points at the real nature of the bet: Gerresheimer is selling the part of its business least likely to spring surprises and keeping the part whose future is more uncertain in both directions.
Doing that under financial pressure sharpens the risk. A company making this pivot from strength could hold the stable assets and pivot gradually. A company making it while deleveraging has to sell the steady cash flow now, which means it is funding a growthier, less certain future by giving up the dependable present, at a moment when it cannot command full value for what it sells. If the injectables bet pays off, the focus will look wise. If it disappoints, the company will have sold its ballast to chase a wave.
Why the buyer is well positioned
From Apax's side, the logic is the mirror image, and it is why private equity exists. Buying stable, essential, cash-generative businesses from a motivated seller is close to the ideal private-equity transaction. The assets throw off predictable cash that can service acquisition debt, they have market-leading positions that are hard to dislodge, and they were, on the seller's own account, under-invested inside a parent distracted by its own problems and short of capital to fund their expansion.
That last point is the opportunity Apax named directly: as an independent company with fresh backing, the business will have capital to invest in capacity, innovation, and US expansion. Read charitably, that is a real value-creation thesis, assets that were starved inside a struggling conglomerate can grow once given money and focus. Read skeptically, it is a reminder that Gerresheimer is selling businesses whose upside it could not fund itself, which means the growth Apax expects to capture is growth Gerresheimer is handing over. Either way, the buyer is acquiring reliability at a moment when the seller's need to sell works in the buyer's favor on price.
How to read it
The clean way to understand this deal is to hold the two framings against the balance sheet. Gerresheimer's strategic-focus story is genuine as far as it goes: concentrating on injectables and drug delivery is a defensible direction, and shedding non-core plastic packaging fits it. But the timing and the CFO's own emphasis on leverage make clear that this is at least as much a deleveraging sale as a strategic one, and deleveraging sales are made from weakness. The company is trading dependable cash flow for a growthier but less certain future, and doing it when it has limited power to hold out for the best terms.
For Apax, the transaction is the familiar and often lucrative private-equity move of acquiring boring, essential, well-run assets from a seller who needs to sell, then funding the expansion the previous owner could not. Whether it proves a bargain depends on execution and on the price beneath the headline €1.5 billion, which was not fully disclosed, but the structural setup, a patient buyer and a pressured seller, favors the buyer.
The broader lesson is one that recurs whenever a distressed company reshapes itself. The assets that get sold in a deleveraging are often not the weakest ones but the most saleable ones, the stable, dependable businesses that fetch a clean price precisely because they are reliable. A company under pressure ends up parting with its steadiest cash generators to survive, and the buyer on the other side gets to own that reliability, bought at the seller's moment of need. Gerresheimer may well emerge leaner and more focused, and its injectables bet may pay off. But it is worth seeing the deal for what it structurally is: a company selling its dependable present to fund an uncertain future, from a position that let the buyer, not the seller, set the terms of the exchange.
Primary sources
- Private Equity Wire and Reuters (via TradingView) for the €1.5 billion enterprise value including debt, coverage of Centor and the global Primary Packaging Plastics division, the roughly €570 million combined revenue and about 2,400 employees across sixteen sites in nine countries, and the framing of the sale as part of Gerresheimer's balance-sheet repair.
- Gerresheimer's ad-hoc release (via EQS and TradingView) and Premium Beauty News for the deal structure, the separate expected closings of Centor by the end of fiscal 2026 and Primary Packaging Plastics in the first half of fiscal 2027, CEO and CFO statements on regaining strategic flexibility and significantly decreasing leverage, Apax partners' comments on market leadership and capital for US expansion, and the focus on injectables and drug-delivery systems.
- Packaging Gateway and Packaging Journal for background on Gerresheimer's reorganization into new divisions, the planned separation of its moulded glass business, and the 2025 group revenue of about €2.3 billion.
- Morpheus Research for the widely reported context of the roughly 80% share decline from the 2023 peak, the approximately €800 million Bormioli Pharma acquisition and resulting leverage near 4.15x against a 4.25x covenant, the BaFin accounting investigation, and the contested short-seller view that certain specialized syringe formats face duration risk, presented here as an analyst opinion rather than established fact.